Clinical Research Directory
Browse clinical research sites, groups, and studies.
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Sponsor: Hunan Province Tumor Hospital
Summary
This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.
Official title: A Prospective, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer With Previous Chemotherapy Combined With PD-L1 Failure
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-06-01
Completion Date
2025-06-01
Last Updated
2024-09-19
Healthy Volunteers
No
Conditions
Interventions
JS201 combine with Lenvatinib
JS201 300mg i.v Q2wLenvatinib 8mg po. Qd
Locations (1)
Hunan Cancer Hospital
Changsha, Hunan, China